Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

Department of Health Research and Policy, Stanford University, California, USA. pah@smi.stanford.edu

OBJECTIVES: We sought to evaluate the current evidence for an effect of beta-blockade treatment on mortality in patients with congestive heart failure (CHF). BACKGROUND: Although numerous small studies have suggested a benefit with beta-blocker therapy in patients with heart failure, a clear survival benefit has not been demonstrated. A recent combined analysis of several studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a significant survival advantage; however, the total number of events was small. Furthermore, it is unclear if previous studies with other beta-blockers are consistent with this finding. METHODS: Randomized clinical trials of beta-blockade treatment in patients with CHF from January 1975 through February 1997 were identified using a MEDLINE search and a review of reports from scientific meetings. Studies were included if mortality was reported during 3 or more months of follow-up. RESULTS: We identified 35 reports, 17 of which met the inclusion criteria. These studies included 3,039 patients with follow-up ranging from 3 months to 2 years. Beta-blockade was associated with a trend toward mortality reduction in 13 studies. When all 17 reports were combined, beta-blockade significantly reduced all-cause mortality (random effect odds ratio [OR] 0.69, 95% confidence interval [CI] 0.54 to 0.88). A trend toward greater treatment effect was noted for nonsudden cardiac death (OR 0.58, 95% CI 0.40 to 0.83) compared with sudden cardiac death (OR 0.84, 95% CI 0.59 to 1.2). Similar reductions in mortality were observed for patients with ischemic (OR 0.69, 95% CI 0.49 to 0.98) and nonischemic cardiomyopathy (OR 0.69, 95% CI 0.47 to 0.99). The survival benefit was greater for trials of the drug carvedilol (OR 0.54, 95% CI 0.36 to 0.81) than for noncarvedilol drugs (OR 0.82, 95% CI 0.60 to 1.12); however, the difference did not reach statistical significance (p = 0.10). CONCLUSIONS: Pooled evidence suggests that beta-blockade reduces all-cause mortality in patients with CHF. Additional trials are required to determine whether carvedilol differs in its effect from other agents.

This article has been cited by other articles:

				A. H Wu Management of patients with non-ischaemic cardiomyopathy Heart, March 1, 2007; 93(3): 403 - 408. [Full Text] [PDF]

				B. M. Psaty, N. S. Weiss, and C. D. Furberg Recent Trials in Hypertension: Compelling Science or Commercial Speech? JAMA, April 12, 2006; 295(14): 1704 - 1706. [Full Text] [PDF]

				Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]

				R. Willenheimer, D. J. van Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum, P. Ponikowski, A. Skene, L. van de Ven, P. Verkenne, et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation, October 18, 2005; 112(16): 2426 - 2435. [Abstract] [Full Text] [PDF]

				R. Willenheimer Implications of CIBIS III: A Commentary Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 115 - 120. [Abstract] [PDF]

				A. H. Wu, K. D. Aaronson, S. F. Bolling, F. D. Pagani, K. Welch, and T. M. Koelling Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction J. Am. Coll. Cardiol., February 1, 2005; 45(3): 381 - 387. [Abstract] [Full Text] [PDF]

				H. Wang, B. S. Huang, D. Ganten, and F. H.H. Leenen Prevention of Sympathetic and Cardiac Dysfunction After Myocardial Infarction in Transgenic Rats Deficient in Brain Angiotensinogen Circ. Res., April 2, 2004; 94(6): 843 - 849. [Abstract] [Full Text] [PDF]

				P. A. Heidenreich, M. A. Gubens, G. C. Fonarow, M. A. Konstam, L. W. Stevenson, and P. G. Shekelle Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1019 - 1026. [Abstract] [Full Text] [PDF]

				Y. Taniguchi, K. Ueshima, I. Chiba, I. Segawa, N. Kobayashi, M. Saito, and K. Hiramori A New Method Using Pulmonary Gas-Exchange Kinetics To Evaluate Efficacy of {beta}-Blocking Agents in Patients With Dilated Cardiomyopathy Chest, September 1, 2003; 124(3): 954 - 961. [Abstract] [Full Text] [PDF]

				B. M. Psaty, T. Lumley, C. D. Furberg, G. Schellenbaum, M. Pahor, M. H. Alderman, and N. S. Weiss Health Outcomes Associated With Various Antihypertensive Therapies Used as First-Line Agents: A Network Meta-analysis JAMA, May 21, 2003; 289(19): 2534 - 2544. [Abstract] [Full Text] [PDF]

				F. Gustafsson, C. Torp-Pedersen, B. Brendorp, M. Seibaek, H. Burchardt, L. Kober, and for the DIAMOND study group Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function Eur. Heart J., May 1, 2003; 24(9): 863 - 870. [Abstract] [Full Text] [PDF]

				K. E. Ellison, G. E. Hafley, K. Hickey, J. Kellen, J. Coromilas, K. M. Stein, K. L. Lee, A. E. Buxton, and for the MUSTT Investigators Effect of {beta}-Blocking Therapy on Outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT) Circulation, November 19, 2002; 106(21): 2694 - 2699. [Abstract] [Full Text] [PDF]

				J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]

				J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]

				S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF]

				J. M. Brophy, L. Joseph, and J. L. Rouleau {beta}-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis Ann Intern Med, April 3, 2001; 134(7): 550 - 560. [Abstract] [Full Text] [PDF]

				T. Ohtsuka, M. Hamada, G. Hiasa, O. Sasaki, M. Suzuki, Y. Hara, Y. Shigematsu, and K. Hiwada Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 1, 2001; 37(2): 412 - 417. [Abstract] [Full Text] [PDF]

				K. A. Phillips, M. G. Shlipak, P. Coxson, P. A. Heidenreich, M. G. M. Hunink, P. A. Goldman, L. W. Williams, M. C. Weinstein, and L. Goldman Health and Economic Benefits of Increased {beta}-Blocker Use Following Myocardial Infarction JAMA, December 6, 2000; 284(21): 2748 - 2754. [Abstract] [Full Text] [PDF]

				A. Mortara, M. T. La Rovere, G. D. Pinna, R. Maestri, S. Capomolla, and F. Cobelli Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1612 - 1618. [Abstract] [Full Text] [PDF]

				P. S. Watson, G. M. Scalia, A. Galbraith, D. J. Burstow, N. Bett, and C. N. Aroney Reply J. Am. Coll. Cardiol., July 1, 2000; 36(1): 305 - 305. [Full Text] [PDF]

				A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. El Allaf, J. Vitovec, J. Aldershvile, et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) JAMA, March 8, 2000; 283(10): 1295 - 1302. [Abstract] [Full Text] [PDF]

				D. V. Exner, J. A. Reiffel, A. E. Epstein, R. Ledingham, M. J. Reiter, Q. Yao, H. J. Duff, D. Follmann, E. Schron, H. L. Greene, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial J. Am. Coll. Cardiol., August 1, 1999; 34(2): 325 - 333. [Abstract] [Full Text] [PDF]

				G. Guyatt A 75-Year-Old Man With Congestive Heart Failure JAMA, June 23, 1999; 281(24): 2321 - 2328. [Full Text] [PDF]

				D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 916 - 923. [Abstract] [Full Text] [PDF]

				P. S. Macdonald, A. M. Keogh, C. L. Aboyoun, M. Lund, R. Amor, and D. J. McCaffrey Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure J. Am. Coll. Cardiol., March 15, 1999; 33(4): 924 - 931. [Abstract] [Full Text] [PDF]

				K. P. Alexander, E. D. Peterson, C. B. Granger, A. C. Casas, F. Van de Werf, P. W. Armstrong, A. Guerci, E. J. Topol, R. M. Califf, and for the GUSTO-IIB Investigators Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb J. Am. Coll. Cardiol., December 1, 1998; 32(7): 2023 - 2030. [Abstract] [Full Text] [PDF]

				N. L. Smith, G. E. Reiber, B. M. Psaty, S. R. Heckbert, D. S. Siscovick, J. L. Ritchie, N. R. Every, and T. D. Koepsell Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1305 - 1311. [Abstract] [Full Text] [PDF]